Home > Boards > US OTC > Biotechs >

Regen BioPharma Inc (RGBP)

RGBP RSS Feed
Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, Bigfootbud, pumper_stumper, Carter, Huggy Bear, joe botts
Search This Board: 
Last Post: 5/18/2022 9:40:25 PM - Followers: 1118 - Board type: Free - Posts Today: 31

Picture

Regen BioPharma 
Followers: 388 Since 10/10/19

 0.000x  Ticker Symbol: RGBP 
Last iBox update 08/09/2020 4PM by CrazyKar123

Barchart


HOT NEWS 

Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation


All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html




 
 

Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.


Telephone: (619) 702-1404
Fax: (619) 330-2328




Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia




     
Image result for cbd


 

Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease

 

SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."

 

 







REMEMBER
Always research for yourself BEFORE you buy in the OTC !!!!

RGBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RGBP News: Current Report Filing (8-k) 05/17/2022 06:08:02 AM
RGBP News: Quarterly Report (10-q) 04/21/2022 04:36:58 AM
RGBP News: Current Report Filing (8-k) 03/18/2022 12:26:29 PM
RGBP News: Current Report Filing (8-k) 02/18/2022 08:19:45 AM
RGBP News: Regen BioPharma to start mRNA anti-cancer vaccine development program 02/11/2022 04:40:56 AM
PostSubject
#106600  Sticky Note 1 BILLION new shares authorized, necessary, due to pumper_stumper 04/03/22 05:39:30 PM
#105377  Sticky Note Great news: Regen BioPharma, Inc. Announces Program to sharky 03/10/22 08:27:11 AM
#41420  Sticky Note RGBP/Zander patents... gotinearly 03/29/21 09:43:29 AM
#108466   Gee, I'm glad! Musical Shares 05/18/22 09:39:19 PM
#108465   Wonder what IP properties Regen has versus what ronrooster 05/18/22 09:39:10 PM
#108464   So thankful! joe botts 05/18/22 09:29:04 PM
#108463   I'm waiting to hear the results from his Musical Shares 05/18/22 08:02:14 PM
#108462   The only thing that matters is that he SidVicious 05/18/22 07:15:27 PM
#108461   Coventry Enterprises LLC is a business ran by Musical Shares 05/18/22 06:18:19 PM
#108460   https://otc.financial/list-of-market-maker-signals/#700-911 art35 05/18/22 05:12:59 PM
#108459   I am so pleased folks have spotted this!! stokbrokin 05/18/22 04:08:33 PM
#108458   Looks like he is selling them right now.And art35 05/18/22 03:55:45 PM
#108457   Have no fear! The debt holder probably pumper_stumper 05/18/22 03:51:43 PM
#108456   That's a nice opinion as is usually the SidVicious 05/18/22 02:49:38 PM
#108455   No one even pumping this garbage now. LandPro 05/18/22 02:34:27 PM
#108454   https://twitter.com/StackerShit/status/1526963404942061574 Rushnattack 05/18/22 02:20:04 PM
#108453   Too bad it will never happen under the SidVicious 05/18/22 01:20:00 PM
#108452   Dr Thomas Ichim : Great question ! Since they TAKURI 05/18/22 01:01:50 PM
#108451   Remember, facts just can not get in the SidVicious 05/18/22 12:42:51 PM
#108450   Let's have fun! Remember on March pumper_stumper 05/18/22 10:45:29 AM
#108449   really not sure Sid. I was just pointing StocktonCA 05/18/22 10:38:57 AM
#108448   Just curious to know that if there have SidVicious 05/18/22 10:19:22 AM
#108447   Csti has the same amt of shares 911911 StocktonCA 05/18/22 10:09:07 AM
#108446   Cdel has 911911 on the ask at .0042 StocktonCA 05/18/22 10:06:52 AM
#108445   Here's a question that I am not sure SidVicious 05/18/22 10:00:43 AM
#108444   KCL Therapeutics, Inc., a wholly-owned subsidiary of Regen TAKURI 05/18/22 09:27:15 AM
#108441   https://www.google.com/search?q=coventry+enterprises+llc&sxsrf=ALiCzsZFfR3w8ZiDZ aheadofthecurve 05/18/22 08:48:13 AM
#108440   Looked yesterday, there was nothing, only mention with aheadofthecurve 05/18/22 08:45:05 AM
#108439   Yeah and who is Coventry? About as much aheadofthecurve 05/18/22 08:29:41 AM
#108436   Updates from Koos on twitter... tcubed 05/17/22 11:36:48 PM
#108435   This is definitely a Charlie Brown stock noode12 05/17/22 09:09:46 PM
#108433   Moving the goal posts isn't going to work. Musical Shares 05/17/22 09:05:57 PM
#108432   RGBP 8M HERE LONG TERM !!! isnt this okwife 05/17/22 07:50:35 PM
#108430   rgbp--->koosimodo_OPENED_A_CAN_OF_WORMS_&.....ATE_THEM_OOPS! Sat Naam 05/17/22 06:18:03 PM
#108428   Just wait until the news hits that Koos SidVicious 05/17/22 05:56:41 PM
#108426   I can't, for the life of me, understand SidVicious 05/17/22 05:37:22 PM
#108425   The suspense is killing me! SidVicious 05/17/22 05:25:52 PM
#108424   never underestimate just how emotional investors can get SidVicious 05/17/22 04:53:44 PM
#108423   This is all old news, and was discussed pumper_stumper 05/17/22 04:28:53 PM
#108422   Actually this 8k is highly unusual. Why would Schuller 05/17/22 04:25:03 PM
#108421   Can you provide a verification link to this art35 05/17/22 04:03:20 PM
#108420   We're in the home stretch (on Yard renovation, The Law (f/k/a emz) 05/17/22 04:03:13 PM
#108419    Maker Trading SignalLevel 2 Market Maker Direction Description 1. StocktonCA 05/17/22 04:00:40 PM
#108418   I always feel better about RGBP when you tcubed 05/17/22 03:31:10 PM
#108417   Note he's not touching the preferred. Also the Schuller 05/17/22 03:17:53 PM
#108416   Does not matter. FORCED or FORCED is raja48185 05/17/22 03:12:48 PM
#108415   They WERE FORCED to pay in shares due pumper_stumper 05/17/22 03:10:53 PM
#108414   Yes, fact is they accepted shares instead of raja48185 05/17/22 03:08:06 PM
#108413   So what? Your initial point attempted to say pumper_stumper 05/17/22 03:06:23 PM
#108412   If (and yes, it's a really big if) The Law (f/k/a emz) 05/17/22 02:59:08 PM
#108411   Absolutely! DAYS....AWAY....FROM.....HUGE.....NEWS! SidVicious 05/17/22 02:57:52 PM
#108410   Fully needs to make money also. So if ECBrat 05/17/22 02:54:17 PM
#108409   So what - he is paying off the raja48185 05/17/22 02:49:20 PM
PostSubject
Consent Preferences